Teosyal is a range of completely synthetic and biodegradable hyaluronic acid-based fillers that are manufactured by Teoxane Laboratories, a leading Swiss pharmaceutical company.
This brand consists of two collections of fillers that are differentiated by the formulations of the injectable gels and the aesthetic imperfections that they are indicated for. The Teosyal brand comprises the following formulations:
- Teosyal PureSense: This collection includes Global Action, Deep Lines, Ultra Deep, Ultimate, and Kiss.
- Teosyal RHA (Resilient Hyaluronic Acid): This collection is made up of Teosyal RHA 1, RHA 2, RHA 3, and RHA 4.
Teoxane Laboratories also manufactures Teosyal Meso, a mesotherapy filler that consists of a high concentration of non-cross-linked hyaluronic acid. It is injected into the superficial dermis layer of the skin in order to rehydrate and rejuvenate the skin.
Teosyal has also created the first cordless, motorized hyaluronic acid injection system. This innovative medical device—which is known as the Teosyal Pen—injects hyaluronic acid gel slowly into delicate areas with very little risk of pain, redness, and bleeding.
Juvederm is a brand of non-animal based hyaluronic acid soft tissue implants that are designed to last for a long period of time. This brand is manufactured by Allergan and comprises two families of fillers that are differentiated by the processing technology used and the resulting implant texture. These two families are described below:
- Juvederm Ultra: This collection is made up of Ultra Smile, Ultra 2 (also known as Ultra XC), Ultra 3 (also known as Ultra Plus XC), and Ultra 4.
- Juvederm Vycross: This collection is made up of Juvederm Volite, Volbella, Volift, and Voluma.
Another filler called Juvederm Hydrate is a biorevitalizing filler containing cross-linked hyaluronic acid gel that is integrated with the antioxidant mannitol; in many respects, it is similar to Teosyal Meso.
Both dermal filler brands can be used to correct a wide variety of skin problems, including dullness, dehydration, fine lines, severe wrinkles, and sunken facial features.
Similarities between the processing technologies
Teosyal PureSense fillers contain highly pure hyaluronic acid gels that have extremely low protein and bacterial endotoxin levels. These implants are also processed to have a monophasic and homogenous texture. Teosyal RHA fillers are made from long chains of hyaluronic acid that are cross-linked and stabilized via the patented Preserved Network method. This technology ensures that small amounts of 1,4-butanediol diglycidyl ether (BDDE) are used.
The Juvederm Ultra collection’s aesthetic fillers are manufactured using Hylacross Technology, which ensures that the injectable gels have a smooth consistency without any granular texture. Juvederm’s Vycross range is processed using Vycross Technology. This exceptional technology reticulates a high percentage (90%) of low molecular weight hyaluronic acid molecules and a low percentage (10%) of high molecular weight hyaluronic acid molecules, resulting in fillers that are very cohesive and malleable.
Unique selling points
Due to the extremely low bacterial endotoxin level and amount of protein in Teosyal PureSense fillers, they are very safe and able to resist premature degradation caused by free radical damage. Teosyal RHA fillers, on the other hand, are famed for their high stretchability. Once injected into the skin, the fillers from this collection stretch to accommodate various facial movements and withstand premature degradation.
Some Teosyal fillers are packaged in syringes fitted with 25G ultra-thin wall needles, which reduce pain and patient trauma during treatment sessions. The double bevel design and lubrication of these needles facilitates improved skin penetration, better filler placement, and less force on the part of the practitioner
Juvederm’s Ultra and Vycross collections are renowned for their long-lasting fillers that provide natural-looking results. Most Juvederm injectable implants, except for Juvederm Hydrate, are proven to last up to a year in most patients.